GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » EPS (Diluted)

Egyptian International Pharmaceutical Investments (CAI:PHAR) EPS (Diluted) : E£6.01 (TTM As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments EPS (Diluted)?

Egyptian International Pharmaceutical Investments's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was E£1.71. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was E£6.01.

Egyptian International Pharmaceutical Investments's EPS (Basic) for the three months ended in Dec. 2023 was E£1.71. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was E£6.01.

Egyptian International Pharmaceutical Investments's EPS without NRI for the three months ended in Dec. 2023 was E£1.87. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was E£6.44.

During the past 12 months, Egyptian International Pharmaceutical Investments's average EPS without NRIGrowth Rate was 7.10% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 15.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 2.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Egyptian International Pharmaceutical Investments's highest 3-Year average EPS without NRI Growth Rate was 29.10% per year. The lowest was -10.40% per year. And the median was 3.70% per year.


Egyptian International Pharmaceutical Investments EPS (Diluted) Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments EPS (Diluted) Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.21 3.84 3.79 4.99 5.54

Egyptian International Pharmaceutical Investments Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 1.46 2.13 0.71 1.71

Competitive Comparison of Egyptian International Pharmaceutical Investments's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egyptian International Pharmaceutical Investments's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's PE Ratio distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's PE Ratio falls into.



Egyptian International Pharmaceutical Investments EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Egyptian International Pharmaceutical Investments's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(823.306-0)/148.756
=5.53

Egyptian International Pharmaceutical Investments's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(254.6-0)/148.756
=1.71

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£6.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Egyptian International Pharmaceutical Investments EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Traded in Other Exchanges
N/A
Address
1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Headlines

From GuruFocus